​

I-Mab (IMAB) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

IMAB Stock Forecast

I-Mab (IMAB) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $7.75, with a high of $9.00 and a low of $7.00. This represents a 67.03% increase from the last price of $4.64.

- $1 $2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $7.75 Low: $7 Last Closed Price: $4.64

IMAB Stock Rating

I-Mab stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

IMAB Price Target Upside V Benchmarks

TypeNameUpside
StockI-Mab67.03%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts244
Avg Price Target$8.00$7.75$7.75
Last Closing Price$4.64$4.64$4.64
Upside/Downside72.41%67.03%67.03%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2524---6
Sep, 2523---5
Aug, 2523---5
Jul, 2523---5
Jun, 2523---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Andrew FeinH.C. Wainwright$7.00$4.5254.87%50.86%
Oct 03, 2025Leerink Partners$9.00$4.13117.92%93.97%
Sep 10, 2025New Street$7.00$4.1867.46%50.86%
Aug 28, 2025Kumaraguru RajaLoop Capital Markets$8.00$4.2588.24%72.41%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 27, 2025CitigroupBuyBuyhold
Sep 10, 2025BTIGBuyBuyhold
Sep 09, 2025BTIGBuyinitialise
Aug 28, 2025Brookline CapitalBuyBuyhold
Sep 16, 2024Piper SandlerOverweightOverweighthold
Mar 18, 2024Piper SandlerOverweightOverweighthold
Aug 17, 2022NeedhamBuyBuyhold
Jun 07, 2022Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-35 $-26 $-17 $-8 $1 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.07$-30.69$-31.75$-16.53-----
Avg Forecast$3.46$-15.72$-14.70$-11.53$-0.95$-3.44$-2.20$-5.42$-5.86
High Forecast$3.46$-15.72$-14.70$-10.06$-0.50$-2.98$-0.87$-5.42$-5.86
Low Forecast$3.46$-15.72$-14.70$-13.00$-1.38$-3.87$-3.52$-5.42$-5.86
Surprise %133.24%95.23%115.99%43.37%-----

Revenue Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.54B$88.03M$-221.56M$27.64M-----
Avg Forecast$1.19B$495.15M$312.90M$26.27M$5.47M$5.49M$10.98M$21.96M$21.96M
High Forecast$1.19B$10.99B$312.90M$43.63M$5.47M$5.49M$10.98M$21.96M$21.96M
Low Forecast$1.19B$100.37M$312.90M$17.56M$5.47M$5.49M$10.98M$21.96M$21.96M
Surprise %29.16%-82.22%-170.81%5.24%-----

Net Income Forecast

$-3B $-2B $-1B $-700M $-100M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$470.92M$-2.33B$-2.41B$-1.47B-----
Avg Forecast$288.22M$-1.31B$-1.22B$-2.21B$-180.04M$-656.08M$-420.33M$-1.04B$-1.12B
High Forecast$288.22M$-1.31B$-1.22B$-1.93B$-95.60M$-570.72M$-165.92M$-1.04B$-1.12B
Low Forecast$288.22M$-1.31B$-1.22B$-2.49B$-264.48M$-741.45M$-674.74M$-1.04B$-1.12B
Surprise %63.39%78.22%97.13%-33.60%-----

IMAB Forecast FAQ

Is I-Mab stock a buy?

I-Mab stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that I-Mab is a favorable investment for most analysts.

What is I-Mab's price target?

I-Mab's price target, set by 11 Wall Street analysts, averages $7.75 over the next 12 months. The price target range spans from $7 at the low end to $9 at the high end, suggesting a potential 67.03% change from the previous closing price of $4.64.

How does I-Mab stock forecast compare to its benchmarks?

I-Mab's stock forecast shows a 67.03% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for I-Mab over the past three months?

  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is I-Mab’s EPS forecast?

I-Mab's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.95, marking a -94.25% decrease from the reported $-16.53 in 2023. Estimates for the following years are $-3.44 in 2025, $-2.2 in 2026, $-5.42 in 2027, and $-5.86 in 2028.

What is I-Mab’s revenue forecast?

I-Mab's average annual revenue forecast for its fiscal year ending in December 2024 is $5.47M, reflecting a -80.20% decrease from the reported $27.64M in 2023. The forecast for 2025 is $5.49M, followed by $10.98M for 2026, $21.96M for 2027, and $21.96M for 2028.

What is I-Mab’s net income forecast?

I-Mab's net income forecast for the fiscal year ending in December 2024 stands at $-180M, representing a -87.72% decrease from the reported $-1.466B in 2023. Projections indicate $-656M in 2025, $-420M in 2026, $-1.037B in 2027, and $-1.121B in 2028.